GLAXO WELLCOME TARGETS MIGRAINE SUFFERERS IN CANADA
By Adnews Staff
U.K.-based Glaxo Wellcome PLC recently brought its new migraine headache treatment drug to the Canadian market. Called Amerge, the drug is used in the treatment of moderate to severe migraines, can be taken any time after a migraine starts and has few side effects. The drug will be promoted using ads in medical journals and PR. The ads will be created by LBJ FRB Communications of Toronto, while Veritas Communications of Toronto will handle PR. Glaxo Wellcome began treating migraine headaches six years ago with the launch of Imitrex, a treatment for severe migraines.
« Back Next »
Comments
blog comments powered by Disqus